XPO1 inhibition in NPM1 mutated AML provides multiple targetable strategies either as monotherapy or in combination with, e.g., menin/KMT2A inhibitors [52], as it was shown to decrease expression of HOX/Meis1 as well. Here, XPO1 is linked to acute myeloid leukemia.